Bicara Therapeutics Inc. (Nasdaq: BCAX) announced its financial results for the third quarter ended September 30, 2026, alongside an update on its clinical development programs. The company reported a net loss of $71.2 million for the quarter, compared to a loss of $36.3 million in the prior year period.
Research and development expenses for the quarter totaled $56.5 million, a significant increase from $33.0 million in the third quarter of 2025. The company attributes this rise to costs associated with the ongoing FORTIFI-HN01 pivotal trial, the FORTIFI-FLEX study, and Phase 1/1b dose expansion cohorts. General and administrative expenses also increased to $19.2 million from $7.7 million, driven by personnel costs and professional fees related to organizational expansion and preparation for potential commercialization.
As of September 30, 2026, Bicara held $442.3 million in cash, cash equivalents, and marketable securities. The company stated that its current cash balance is expected to fund operations into the first half of 2029.
On the clinical front, Bicara reported substantial enrollment in the FORTIFI-HN01 pivotal trial for first-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma (HNSCC). The company anticipates topline results from an interim analysis of this trial in mid-2027. Additionally, the company is enrolling the FORTIFI-FLEX study, which is evaluating a 12-week loading dose followed by maintenance dosing of ficerafusp alfa in combination with pembrolizumab. Bicara expects to have data from this alternate dosing study by the time of a potential U.S. approval for the indication.
Looking ahead, the company plans to present data from a Phase 1b expansion cohort in metastatic colorectal cancer in January 2027 and preclinical data at the ESMO Immuno-Oncology & Advanced Therapies Congress in December 2026.
